Results 101 to 110 of about 731 (176)

Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms. [PDF]

J Hematol Oncol
Arora S, Senapati J, Deshmukh I, Bose P, Masarova L, Loghavi S, Wang X, Nogueras-Gonzalez G, Montalban-Bravo G, Borthakur G, DiNardo CD, Kadia T, Zhou L, Saenz D, Halim H, Alvarado Y, Ohanian M, Takahashi K, Short NJ, Jabbour E, Ravandi F, Garcia-Manero G, Pemmaraju N, Daver NG.   +23 more
europepmc   +1 more source

The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria. [PDF]

ESMO Open
Apolo AB, Bellmunt J, Cordes L, Gupta S, Powles T, Rosenberg JE, Van Der Heijden MS.   +6 more
europepmc   +1 more source

A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patients. [PDF]

Blood Cancer J
Firestone RS, Simhal AK, Akhlaghi T, Oh JH, McAvoy D, Maclachlan KH, Garces JJ, Mailankody S, Hassoun H, Shah UA, Korde N, Tan CR, Rajeeve S, Hashmi H, Lesokhin AM, Hosszu K, Maura F, Deasy JO, Usmani SZ, Hultcrantz M.   +19 more
europepmc   +1 more source

MUVY: A multi-view user-generated sports video dataset. [PDF]

Data Brief
Pessoa L, Alencar E, de Freitas R.
europepmc   +1 more source

ICoN: integration using co-attention across biological networks. [PDF]

Bioinform Adv
Tasnina N, Murali TM.
europepmc   +1 more source

Low Testosterone Levels and Grade Group Progression Among Localized Prostate Cancer Patients on Active Surveillance: A Retrospective Cohort Study. [PDF]

J Urol
Lawen T, Garcia RS, Smith MT, Pyo J, Higgason NM, Robert MJM, Chapin BF, Chery LS, Davis JW, Ward JF, Pisters LL, Pettaway CA, Hahn AW, Frigo DE, Wei P, Daniel CR, Gregg JR.   +16 more
europepmc   +1 more source

Mutations in isocitrate dehydrogenase portend a poor prognosis in adult patients with acute lymphoblastic leukemia. [PDF]

Blood Adv
Goulart H, Short NJ, Borthakur G, Jain N, DiNardo C, Loghavi S, Khouri R, Hachem M, Ravandi F, Daver N, Kadia TM, Yilmaz M, Issa G, Bazinet A, Swaminathan M, Montalban-Bravo G, Haddad F, Garris R, Kantarjian H, Jabbour E.   +19 more
europepmc   +1 more source

Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies. [PDF]

Clin Lymphoma Myeloma Leuk
Hamadeh IS, Merz M, Derkach A, Modelevsky L, Lesokhin AM, Mailankody S, Hultcrantz ML, Tan CR, Hassoun H, Shah UA, Maclachlan K, Rajeeve S, Hashmi H, Maura F, Firestone RS, Wang AX, Amin A, Patel D, Scordo M, Shah GL, Landau HJ, Giralt S, Usmani SZ, Korde N.   +23 more
europepmc   +1 more source

The patient voice: measuring what matters in lower-risk myelodysplastic syndromes treated with imetelstat. [PDF]

Haematologica
Chien KS, DeZern AE.
europepmc   +1 more source

EXTRA-PC: a phase II trial of masofaniten (EPI-7386) and enzalutamide for patients with treatment-naïve metastatic hormone-sensitive prostate cancer. [PDF]

Oncologist
Jang A, Fowler P, Helminiak K, Kumar HLS, Pasucal J, Delong V, Zhong JY, Jindal T, Grier AL, Patel RR, Hislop M, Cesano A, Villaluna K, Younginger B, Wolff K, Richey K, Bray J, Garcia H, Adamowicz T, Reese A, Nizam A, Gupta S, Wee CE, Margevicius S, Fu P, Mendiratta P, Sheng IY, Brown JR, Garcia JA, Barata PC.   +29 more
europepmc   +1 more source